MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY. Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 ...

Core Viewpoint - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2024, indicating a mixed performance with slight revenue growth in Q4 but an overall decline for the year [1][3]. Financial Highlights - Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, reflecting a 1% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2024 total revenue is projected to be between $79.7 million and $79.9 million, representing a 2% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2024, were approximately $120 million, up from $118.6 million as of September 30, 2024 [4]. Segment Performance - Surgical Glaucoma revenue for Q4 is expected to be between $18.7 million and $18.8 million, a 9% increase at the estimated midpoint compared to Q4 2023 [5][7]. - Dry Eye revenue for Q4 is expected to be between $0.2 million and $0.3 million, a significant decrease from $1.6 million in the prior year [7]. - Full year Surgical Glaucoma revenue is expected to be between $75.8 million and $75.9 million, a 2% increase at the estimated midpoint compared to the previous year [7]. - Full year Dry Eye revenue is expected to be between $3.9 million and $4.0 million, down from $6.7 million in 2023 [7]. Cash Management - Cash generated in Q4 totaled approximately $1.4 million, a significant improvement compared to cash used of $6.4 million in the same period last year [7]. - Total cash used during the year was approximately $18.1 million, a reduction from $46.9 million in the prior year [7]. - The company aims to achieve cash flow breakeven without raising additional equity capital [7]. Strategic Outlook - The company is focused on effective cash management while investing in long-term value drivers, positioning itself well for 2025 with a strong cash position and differentiated technologies [5]. - The company anticipates continued progress towards establishing equitable reimbursed market access for its TearCare product [5].

Core Viewpoint - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2024, indicating a mixed performance with slight revenue growth in Q4 but an overall decline for the year [1][3]. Financial Highlights - Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, reflecting a 1% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2024 total revenue is projected to be between $79.7 million and $79.9 million, representing a 2% decrease at the estimated midpoint compared to the previous year [3]. - Surgical Glaucoma revenue for Q4 2024 is expected to be between $18.7 million and $18.8 million, a 9% increase at the estimated midpoint compared to Q4 2023 [5][7]. - Dry Eye revenue for Q4 2024 is expected to be between $0.2 million and $0.3 million, a significant decrease from $1.6 million in the prior year [7]. - Surgical Glaucoma revenue for the full year 2024 is expected to be between $75.8 million and $75.9 million, a 2% increase at the estimated midpoint compared to the previous year [7]. - Dry Eye revenue for the full year 2024 is expected to be between $3.9 million and $4.0 million, down from $6.7 million in 2023 [7]. - Cash and cash equivalents as of December 31, 2024, were approximately $120 million, up from $118.6 million as of September 30, 2024 [4]. - Cash generated in Q4 totaled approximately $1.4 million, a decrease from $6.4 million cash used in the same period of the prior year [7]. - Total cash used during the year was approximately $18.1 million, significantly down from $46.9 million in the prior year [7]. Strategic Outlook - The company aims to achieve cash flow breakeven without raising additional equity capital, indicating a focus on operational discipline and effective cash management [5][7]. - The company is positioned to execute its long-term vision with a strong cash position and clinically differentiated technologies such as OMNI and TearCare [5].

The study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates sustained intraocular pressure reductions and decreased medication dependenceMENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventiona ...

Budget impact analysis published in the Expert Review of Ophthalmology journalMENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis (“BIA”) of the TearCare® System (“TearCare”) for the treatment of MGD-associated dry eye disease (“DED” ...

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis ("BIA") of the TearCare® System ("TearCare") for the treatment of MGD-associated dry eye disease ("DED") in the United States. A BIA estimates the fiscal impact of adopting a new tec ...

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Intereste ...

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.35%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.25, delivering a surprise of 19.35%.Over the last four quarters, the company has surp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share SGHT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro ...

Exhibit 99.1 Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the third quarter ended September 30, 2024, and updated it ...